Core Viewpoint - The approval of the injectable Cefoperazone Sodium and Sulbactam Sodium by the National Medical Products Administration of China enhances the company's position in the anti-infection sector and is expected to generate greater returns for the company and its shareholders [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for the injectable Cefoperazone Sodium and Sulbactam Sodium (specification: 2.0g) [1] - This product has passed the consistency evaluation for generic drug quality and efficacy [1] Group 2: Product Characteristics - Injectable Cefoperazone Sodium and Sulbactam Sodium is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity [1] - It can be used alone or in combination for treating infections caused by sensitive bacteria, including respiratory, urinary, intra-abdominal infections, sepsis, meningitis, skin and soft tissue infections, bone and joint infections, and reproductive tract infections [1] Group 3: Market Position and Future Plans - The product is listed as a Class B drug in the National Medical Insurance Directory (2024 edition) [1] - The approval is expected to help the company strengthen its competitive advantage in the anti-infection field [1] - The company will continue to focus on new product development and advancing consistency evaluations to create greater value for the company and its shareholders [1]
联邦制药(03933.HK)：注射用头孢哌酮钠舒巴坦钠通过一致性评价